TRPV1 and Alzheimer disease: In a randomized, vehicle-controlled phase 3 study involving patients aged 12 and older with mild-to-moderate AD, the selective TRPV-1 antagonist asivatrep exhibited efficacy in improving eczematous lesions and alleviating itch [52].